review Open AccessTop 1% cited

Circulating Tumor DNA as a Liquid Biopsy for Cancer

Clinical Chemistry · 2014 · Vol. 61(1) · pp. 112–123

Ellen Heitzer✉(Medical University of Graz)Peter Ulz(Medical University of Graz)Jochen B. Geigl(Medical University of Graz)

View via DOI Full-text PDF

Abstract

Although the analysis of ctDNA is a promising area, and despite all efforts to develop suitable tools for a comprehensive analysis of tumor genomes from plasma DNA, the liquid biopsy is not yet routinely used as a clinical application. Harmonization of preanalytical and analytical procedures is needed to provide clinical standards to validate the liquid biopsy as a clinical biomarker in well-designed and sufficiently powered multicenter studies.

Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations Genetic factors in colorectal cancerLiquid biopsyBiopsyMedicineGenotypingBiomarkerCirculating tumor DNACell-free fetal DNACancerComputational biologyOncology

MeSH terms

BiopsyDNA, NeoplasmHumansNeoplasmsPredictive Value of TestsPrognosisProto-Oncogene ProteinsBiomarkers, TumorProto-Oncogene Proteins p21(ras)Sequence Analysis, DNAras ProteinsErbB Receptors

Citations

750

FWCI

23.86

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma